DARE (STOCKS)
Dare Bioscience, Inc. Common Stock
$1.720000
+0.030000 (+1.78%)
Prev close: $1.690000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sabrina Martucci Johnson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $24.65M
- Employees
- 23
- P/E (TTM)
- -3.90
- P/B (TTM)
- 8.24
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | -$57.13K |
| Benefits Costs and Expenses | $4.06M |
| Costs And Expenses | -$1.99M |
| Operating Expenses | $17.41M |
| Research and Development | $8.14M |
| Other Operating Expenses | $9.27M |
| Operating Income/Loss | -$17.47M |
| Income/Loss From Continuing Operations After Tax | -$17.46M |
| Income/Loss From Continuing Operations Before Tax | -$4.12M |
| Net Income/Loss | -$17.46M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$17.46M |
| Net Income/Loss Available To Common Stockholders, Basic | -$17.46M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.83 |
| Diluted Earnings Per Share | -$1.83 |
| Basic Average Shares | 9,983,681 |
| Diluted Average Shares | 9,956,927 |
| Assets | $30.75M |
| Current Assets | $25.00M |
| Prepaid Expenses | $1.51M |
| Other Current Assets | $23.50M |
| Noncurrent Assets | $5.74M |
| Fixed Assets | $1.66M |
| Other Non-current Assets | $4.09M |
| Liabilities | $27.89M |
| Current Liabilities | $21.22M |
| Accounts Payable | $1.84M |
| Other Current Liabilities | $19.37M |
| Noncurrent Liabilities | $6.67M |
| Equity | $2.86M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.86M |
| Liabilities And Equity | $30.75M |
| Net Cash Flow From Operating Activities | -$6.10M |
| Net Cash Flow From Operating Activities, Continuing | -$6.10M |
| Net Cash Flow From Investing Activities | -$741.49K |
| Net Cash Flow From Investing Activities, Continuing | -$741.49K |
| Net Cash Flow From Financing Activities | $18.72M |
| Net Cash Flow From Financing Activities, Continuing | $18.72M |
| Exchange Gains/Losses | -$33.34K |
| Net Cash Flow | $11.84M |
| Net Cash Flow, Continuing | $11.91M |
| Comprehensive Income/Loss | -$17.50M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$17.50M |
| Other Comprehensive Income/Loss | -$17.50M |